Hangzhou Tigermed Consulting Co., Ltd. Class H (HK:3347) has released an update.
Hangzhou Tigermed Consulting Co., Ltd. reported a decline in its financial performance for the first half of 2024, with a 9.5% drop in revenue and a 64.5% decrease in net profit attributable to owners, compared to the same period in 2023. Despite this, the biopharmaceutical industry in China and globally shows signs of recovery, with increased financing, higher numbers of approved innovative drugs, and more clinical trials. The company did not declare an interim dividend for this period, maintaining the same stance as the previous year.
For further insights into HK:3347 stock, check out TipRanks’ Stock Analysis page.
